London · Delayed Price · Currency is GBP · Price in GBX Anpario Earnings Call Transcripts
Fiscal Year 2025
-
Revenue rose 34% year-over-year, with strong growth across most regions and a significant contribution from the Bio-Vet acquisition. Gross margin and profitability improved, cash reserves increased, and the outlook remains positive despite ongoing trade and credit risks.
Fiscal Year 2024
-
Revenue and profit rebounded strongly, with all regions and product classes growing and gross margin improving to 46.9%. The Bio-Vet acquisition added significant U.S. presence and product capabilities, while a robust cash position supports ongoing dividends and future growth.
-
Sales growth is accelerating in H2, with gross margins recovering to 47.5% and strong momentum in Asia, the Middle East, and India. Management targets high single-digit sales growth, supported by operational gearing and acquisitions, while navigating regulatory and logistics risks.